Meeting
2024 ASCO Genitourinary Cancers Symposium
A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).
Authors
Ulrich Krafft
University Hospital Essen, Universtity Duisburg-Essen, Germany, Essen, Germany
Ulrich Krafft , Viktor Grünwald , Wolfgang P. Fendler , Ken Herrmann , Henning Reis , Florian Roghmann , Kambiz Rahbar , Axel Heidenreich , Frederik Giesel , Guenter Niegisch , Boris A. Hadaschik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
EudraCT-Nr.: 2021-004894-30
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS352)
DOI
10.1200/JCO.2024.42.4_suppl.TPS352
Abstract #
TPS352
Poster Bd #
R4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.
First Author: Rana R. McKay
Poster
2022 ASCO Genitourinary Cancers Symposium
A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.
First Author: David James VanderWeele
Poster
2017 Genitourinary Cancers Symposium
Stereotactic body radiotherapy for high-risk prostate cancer (5 Treatment Days): Toxicity results of a phase II trial.
First Author: Amar Upadhyaya Kishan
Poster
2012 Genitourinary Cancers Symposium
The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial.
First Author: Jodi Lyn Layton